In Q4 2023, Rock Springs Capital held 79 positions worth $3.4B. They initiated 3 new positions and exited 21. Their largest holding was BPMC ($265.8M). Portfolio value grew +8.0% versus the prior quarter.
Frequently asked questions
What stocks did Rock Springs Capital own in Q4 2023?
Rock Springs Capital held 79 biotech stocks in their 13F portfolio in Q4 2023. Their top positions include BPMC, IMCR, NBIX, HUM, PEN. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Rock Springs Capital's portfolio worth in Q4 2023?
Rock Springs Capital's tracked biotech portfolio was worth $3.4B across 79 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Rock Springs Capital buy in Q4 2023?
Rock Springs Capital initiated 3 new positions in Q4 2023, including LLY, GPCR, OSCR. They also increased 31 existing positions.
What did Rock Springs Capital sell in Q4 2023?
Rock Springs Capital fully exited 21 positions in Q4 2023, including VERV, RXDX, NVCR, GH, CNMD and 16 more. They also trimmed 21 existing positions.
Is Rock Springs Capital a biotech fund?
Concentrated long/short healthcare fund focused on fundamental research. Rock Springs takes conviction-weighted positions based on deep pipeline analysis, therapeutic area expertise, and a willingness to be contrarian when the science supports it.
Want AI analysis, insider signals, and catalyst overlays for Rock Springs Capital?
View latest Rock Springs Capital portfolio →